PubRank

W März

Author PubWeight™ 114.86‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Association of vitamin D status with serum androgen levels in men. Clin Endocrinol (Oxf) 2009 1.94
2 Rationale and design of the LURIC study--a resource for functional genomics, pharmacogenomics and long-term prognosis of cardiovascular disease. Pharmacogenomics 2001 1.91
3 Human connective tissue growth factor is expressed in advanced atherosclerotic lesions. Circulation 1997 1.67
4 Deletion polymorphism of the angiotensin I-converting enzyme gene is associated with increased plasma angiotensin-converting enzyme activity but not with increased risk for myocardial infarction and coronary artery disease. Ann Intern Med 1996 1.51
5 Immuno-PCR with a commercially available avidin system. Science 1993 1.43
6 Coronary heart disease risk reduction in a predominantly beer-drinking population. Epidemiology 2001 1.40
7 High prevalence of FDB3500 mutation in the Swiss population. Atherosclerosis 2000 1.39
8 Cardiovascular risk factors in primary care: methods and baseline prevalence rates--the DETECT program. Curr Med Res Opin 2005 1.29
9 Association between the A-2518G polymorphism in the monocyte chemoattractant protein-1 gene and insulin resistance and Type 2 diabetes mellitus. Diabetologia 2004 1.26
10 Current infection with Helicobacter pylori, but not seropositivity to Chlamydia pneumoniae or cytomegalovirus, is associated with an atherogenic, modified lipid profile. Arterioscler Thromb Vasc Biol 2001 1.22
11 The Friedewald formula underestimates LDL cholesterol at low concentrations. Clin Chem Lab Med 2001 1.19
12 Apolipoprotein E polymorphism influences not only cerebral senile plaque load but also Alzheimer-type neurofibrillary tangle formation. Neuroscience 1995 1.12
13 Glucokinase-activating GCKR polymorphisms increase plasma levels of triglycerides and free fatty acids, but do not elevate cardiovascular risk in the Ludwigshafen Risk and Cardiovascular Health Study. Horm Metab Res 2010 1.07
14 Apolipoprotein E isoforms and the development of low and high Braak stages of Alzheimer's disease-related lesions. Acta Neuropathol 1999 1.06
15 Unmet needs in the diagnosis and treatment of dyslipidemia in the primary care setting in Germany. Atherosclerosis 2006 1.05
16 Visfatin/pre-B-cell colony-enhancing factor: a protein with various suggested functions. J Endocrinol Invest 2007 1.03
17 Rationale and design of a trial improving outcome of type 2 diabetics on hemodialysis. Die Deutsche Diabetes Dialyse Studie Investigators. Kidney Int Suppl 1999 1.01
18 Infection with Helicobacter pylori is not a major independent risk factor for stable coronary heart disease: lack of a role of cytotoxin-associated protein A-positive strains and absence of a systemic inflammatory response. Circulation 1999 1.01
19 The effect of anastrozole on the single-dose pharmacokinetics and anticoagulant activity of warfarin in healthy volunteers. Br J Clin Pharmacol 2001 0.99
20 The fatty liver index is associated with increased mortality in subjects referred to coronary angiography. Nutr Metab Cardiovasc Dis 2013 0.99
21 Genetic variants and haplotypes of lipoprotein associated phospholipase A2 and their influence on cardiovascular disease (The Ludwigshafen Risk and Cardiovascular Health Study). J Thromb Haemost 2008 0.99
22 Left main coronary artery stenosis after aortic valve replacement: genetic disposition for accelerated arteriosclerosis after injury of the intact human coronary artery? Coron Artery Dis 1993 0.98
23 Different effects of abciximab and cytochalasin D on clot strength in thrombelastography. J Thromb Haemost 2004 0.98
24 Haplotypes of the cholesteryl ester transfer protein gene predict lipid-modifying response to statin therapy. Pharmacogenomics J 2003 0.96
25 Rosuvastatin reduces interleukin-6-induced expression of C-reactive protein in human hepatocytes in a STAT3- and C/EBP-dependent fashion. Int J Clin Pharmacol Ther 2007 0.93
26 Low density lipoprotein (LDL) subfractions during pregnancy: accumulation of buoyant LDL with advancing gestation. J Clin Endocrinol Metab 2000 0.93
27 The serotonin transporter gene polymorphism is not associated with smoking behavior. Pharmacogenomics J 2006 0.93
28 Angiotensinogen M235T polymorphism is associated with plasma angiotensinogen and cardiovascular disease. Am Heart J 1999 0.93
29 Rapid genotyping of human platelet antigen 1 (HPA-1) with fluorophore-labelled hybridization probes on the LightCycler. Br J Haematol 1999 0.92
30 Molecular basis of type III hyperlipoproteinemia in Germany. Hum Mutat 1998 0.92
31 Quantitative determination of high-, low-, and very-low-density lipoproteins and lipoprotein(a) by agarose gel electrophoresis and enzymatic cholesterol staining. Clin Chem 1995 0.91
32 Interleukin-6 stimulates LDL receptor gene expression via activation of sterol-responsive and Sp1 binding elements. Arterioscler Thromb Vasc Biol 2000 0.91
33 Diminished LDL receptor and high heparin binding of apolipoprotein E2 Sendai associated with lipoprotein glomerulopathy. J Am Soc Nephrol 2001 0.91
34 Rapid, homogeneous genotyping of the 4G/5G polymorphism in the promoter region of the PAII gene by fluorescence resonance energy transfer and probe melting curves. Clin Chem 1999 0.90
35 Effect of atorvastatin, simvastatin, and lovastatin on the metabolism of cholesterol and triacylglycerides in HepG2 cells. Biochem Pharmacol 2001 0.90
36 Detection of mutations in the apolipoprotein CII gene by denaturing gradient gel electrophoresis. Identification of the splice site variant apolipoprotein CII-Hamburg in a patient with severe hypertriglyceridemia. Clin Chem 1998 0.89
37 Postprandial triglyceride high response and the metabolic syndrome. Ann N Y Acad Sci 1997 0.89
38 Homozygous familial defective apolipoprotein B-100. Enhanced removal of apolipoprotein E-containing VLDLs and decreased production of LDLs. Arterioscler Thromb Vasc Biol 1997 0.88
39 Effect of HMG CoA reductase inhibitors on low-density lipoprotein cholesterol and C-reactive protein: systematic review and meta-analysis. Int J Clin Pharmacol Ther 2008 0.88
40 Rapid detection of the C3435T polymorphism of multidrug resistance gene 1 using fluorogenic hybridization probes. Clin Chem 2000 0.87
41 Multicenter evaluation of a homogeneous assay for HDL-cholesterol without sample pretreatment. Clin Chem 1997 0.87
42 Coronary artery disease and dyslipidemia within Europe: genetic variants in lipid transport gene loci in German subjects with premature coronary artery disease. Atheroscler Suppl 2002 0.86
43 IgG antibodies against food antigens are correlated with inflammation and intima media thickness in obese juveniles. Exp Clin Endocrinol Diabetes 2007 0.85
44 Glucagon-like peptide 1 increases secretory burst mass of pulsatile insulin secretion in patients with type 2 diabetes and impaired glucose tolerance. Diabetes 2001 0.85
45 [Cardiovascular high-risk constellations in primary care. DETECT Study 2003]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2005 0.85
46 Apolipoprotein E isoforms increase intracellular Ca2+ differentially through a omega-agatoxin IVa-sensitive Ca2+-channel. Brain Pathol 1998 0.84
47 Cigarette smoking is independently associated with markers of endothelial dysfunction and hyperinsulinaemia in nondiabetic individuals with coronary artery disease. Curr Med Res Opin 2001 0.84
48 [Longitudinal associations between depressive symptoms and type 2 diabetes and their impact on mortality in primary care patients]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2011 0.84
49 Homocysteine and methylenetetrahydrofolate reductase genotype: association with risk of coronary heart disease and relation to inflammatory, hemostatic, and lipid parameters. Atherosclerosis 2002 0.84
50 Uric acid is predictive of cardiovascular mortality and sudden cardiac death in subjects referred for coronary angiography. Nutr Metab Cardiovasc Dis 2011 0.83
51 Chronic selective hypertriglyceridemia impairs endothelium-dependent vasodilatation in rats. Cardiovasc Res 1999 0.83
52 Cerebrospinal fluid apolipoprotein E (apoE) levels in Alzheimer's disease patients are increased at follow up and show a correlation with levels of tau protein. Neurosci Lett 1997 0.83
53 Apolipoprotein E1 Baden (Arg(180)-->Cys). A new apolipoprotein E variant associated with hypertriglyceridemia. Clin Chim Acta 2001 0.82
54 Qualitative effect of fenofibrate and quantitative effect of atorvastatin on LDL profile in combined hyperlipidemia with dense LDL. Exp Clin Endocrinol Diabetes 2004 0.82
55 Differential effects of fluvastatin alone or in combination with ezetimibe on lipoprotein subfractions in patients at high risk of coronary events. Eur J Clin Invest 2010 0.82
56 A new liquid homogeneous assay for HDL cholesterol determination evaluated in seven laboratories in Europe and the United States. Clin Chem Lab Med 2000 0.82
57 Competition of Abeta amyloid peptide and apolipoprotein E for receptor-mediated endocytosis. J Lipid Res 1999 0.82
58 Low-density lipoprotein susceptibility to in vitro oxidation in healthy smokers and nonsmokers. Clin Chem 1996 0.82
59 Asymmetric dimethylarginine (ADMA) is tightly correlated with growth in juveniles without correlations to obesity related disorders. Exp Clin Endocrinol Diabetes 2008 0.82
60 Is the determination of LDL cholesterol according to Friedewald accurate in CAPD and HD patients? Clin Nephrol 1996 0.82
61 The lipoprotein lipase HindIII polymorphism: association with total cholesterol and LDL-cholesterol, but not with HDL and triglycerides in 342 females. Clin Chem 1999 0.81
62 Neonatal monitoring to assess risk for hypertension. Postgrad Med 1986 0.81
63 HDL steady state levels are not affected, but HDL apoA-I turnover is enhanced by Lifibrol in patients with hypercholesterolemia and mixed hyperlipidemia. Atherosclerosis 2000 0.81
64 Determination of pravastatin by high performance liquid chromatography. Int J Clin Pharmacol Ther 2000 0.81
65 Apolipoprotein A-IV concentrations and clinical outcomes in haemodialysis patients with type 2 diabetes mellitus--a post hoc analysis of the 4D Study. J Intern Med 2012 0.81
66 Hyperbaric indices (HBI) assess the extent and timing of deviant blood pressure in patients under treatment. Chronobiologia 1987 0.81
67 Altered lipid metabolism in preeclampsia and HELLP syndrome: links to enhanced platelet reactivity and fetal growth. Semin Thromb Hemost 1999 0.81
68 A new liquid homogeneous assay for the determination of HDL-cholesterol. A comparison to precipitation with phosphotungstic acid/MgCl2 and a lyophilized homogeneous assay. Clin Chem Lab Med 1999 0.81
69 The L162V polymorphism of the peroxisome proliferator activated receptor alpha gene (PPARA) is not associated with type 2 diabetes, BMI or body fat composition. Exp Clin Endocrinol Diabetes 2008 0.81
70 [Pharmacoeconomic evaluation of pravastatin in the secondary prevention of coronary heart disease in patients with average cholesterol levels. An analysis for Germany based on the CARE study]. Herz 1998 0.81
71 Homoarginine deficiency is associated with increased bone turnover. Osteoporos Int 2012 0.81
72 Association of polymorphisms of platelet membrane integrins alpha IIb(beta)3 (HPA-1b/Pl) and alpha2(beta)1 (alpha807TT) with premature myocardial infarction. J Thromb Haemost 2005 0.81
73 Expression of fat mobilizing genes in human epicardial adipose tissue. Atherosclerosis 2011 0.80
74 Associations of homoarginine with bone metabolism and density, muscle strength and mortality: cross-sectional and prospective data from 506 female nursing home patients. Osteoporos Int 2012 0.80
75 The betaA4 amyloid peptide complexes to and enhances the uptake of beta-very low density lipoproteins by the low density lipoprotein receptor-related protein and heparan sulfate proteoglycans pathway. Lab Invest 1999 0.80
76 Evaluation of the apo E genotyping kit on the LightCycler. Clin Chem 2000 0.80
77 Mutation in coagulation factor V associated with resistance to activated protein C in patients with coronary artery disease. Lancet 1995 0.80
78 Rapid detection of a common dihydropyrimidine dehydrogenase mutation associated with 5-fluorouracil toxicity and congenital thymine uraciluria using fluorogenic hybridization probes. Clin Biochem 2001 0.80
79 Sex steroids and mortality in men referred for coronary angiography. Clin Endocrinol (Oxf) 2010 0.80
80 Apolipoprotein E5 (Glu212-->Lys): increased binding to cell surface proteoglycans but decreased uptake and lysosomal degradation in cultured fibroblasts. J Lipid Res 1996 0.79
81 Lipoprotein (a): a risk factor for retinal vascular occlusion. Ger J Ophthalmol 1992 0.79
82 Mutations in the apolipoprotein (apo) B-100 receptor-binding region: detection of apo B-100 (Arg3500-->Trp) associated with two new haplotypes and evidence that apo B-100 (Glu3405-->Gln) diminishes receptor-mediated uptake of LDL. Clin Chem 1999 0.79
83 Hemoglobin Rambam (beta69[E13]Gly-->Asp), a pitfall in the assessment of diabetic control: characterization by electrospray mass spectrometry and HPLC. Clin Chem 1998 0.79
84 D-thyroxine reduces lipoprotein(a) serum concentration in dialysis patients. J Am Soc Nephrol 1998 0.79
85 [Challenge in diabetes therapy: effects of glitazones beyond blood glucose control]. Dtsch Med Wochenschr 2009 0.79
86 Copper, ceruloplasmin, and long-term cardiovascular and total mortality (the Ludwigshafen Risk and Cardiovascular Health Study). Free Radic Res 2014 0.79
87 C-reactive protein and lipoprotein-associated phospholipase A2 in smokers and nonsmokers of the Ludwigshafen Risk and Cardiovascular Health study. Adv Exp Med Biol 2015 0.79
88 Association of bone turnover markers with mortality in men referred to coronary angiography. Osteoporos Int 2012 0.79
89 High estradiol levels are associated with increased mortality in older men referred to coronary angiography. Exp Clin Endocrinol Diabetes 2011 0.79
90 Circadian systolic and diastolic differences (CSDD) and circadian modulation of 1.7-h ultradians. Chronobiologia 1987 0.79
91 Identification of recurrent and novel mutations in the LDL receptor gene in German patients with familial hypercholesterolemia. Hum Mutat 2001 0.79
92 Circadian variability of blood pressure and heart rate in newborns and cardiovascular chronorisk. Prog Clin Biol Res 1987 0.79
93 Determination of triglycerides in lipoproteins separated by agarose gel electrophoresis. J Lipid Res 1995 0.78
94 Lipid-lowering medication for secondary prevention of coronary heart disease in a German outpatient population: the gap between treatment guidelines and real life treatment patterns. Prev Med 2002 0.78
95 The HMG-CoA reductase inhibitor cerivastatin lowers advanced glycation end products in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes 2007 0.78
96 Evaluation of the Roche Diagnostics LightCycler-Apo B 3500 Mutation Detection Kit. Clin Chem Lab Med 2000 0.78
97 Is lipoprotein(a) cholesterol a significant indicator of cardiovascular risk? Clin Chem 2000 0.78
98 Experimental acute hypoxia in healthy subjects: evaluation of systolic and diastolic function of the left ventricle at rest and during exercise using echocardiography. Eur J Appl Physiol Occup Physiol 1995 0.78
99 Increased production of HDL ApoA-I in homozygous familial defective ApoB-100. Arterioscler Thromb Vasc Biol 2000 0.78
100 Polymorphism of platelet membrane glycoprotein IIIa: human platelet antigen 1b (HPA-1b/PlA2) is an inherited risk factor for premature myocardial infarction in coronary artery disease. Thromb Haemost 1998 0.78
101 Evolving biomarkers improve prediction of long-term mortality in patients with stable coronary artery disease: the BIO-VILCAD score. J Intern Med 2014 0.78
102 Characterization of transgenic mice expressing apolipoprotein E4(C112R) and apolipoprotein E4(L28P; C112R). Neuroscience 2000 0.78
103 Elevated endothelin levels in patients with hyperlipoproteinemia. Clin Investig 1994 0.78
104 Characterization of the gene for apolipoprotein E5-Frankfurt (Gln81->Lys, Cys112->Arg) by polymerase chain reaction, restriction isotyping, and temperature gradient gel electrophoresis. Electrophoresis 1993 0.78
105 [Cost effectiveness of pravastatin in secondary coronary prevention in patients with myocardial infarct or unstable angina in Germany. An analysis on the basis of the LIPID trial]. Herz 2000 0.78
106 Apolipoprotein E3Basel: new insights into a highly conserved protein region. Eur J Clin Invest 2003 0.78
107 A randomized cross-over comparison of two low-dose oral contraceptives upon hormonal and metabolic parameters: I. Effects upon sexual hormone levels. Contraception 1985 0.78
108 The effects of lifibrol (K12.148) on the cholesterol metabolism of cultured cells: evidence for sterol independent stimulation of the LDL receptor pathway. Atherosclerosis 2000 0.77
109 Short- and long-term effects on lipid metabolism of oral contraceptives containing 30 micrograms ethinylestradiol and 150 micrograms desogestrel or 3-keto-desogestrel. Horm Res 1995 0.77
110 Tumour necrosis factor beta alleles and hyperinsulinaemia in coronary artery disease. Eur J Clin Invest 1998 0.77
111 Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A. Int J Clin Pharmacol Ther 2002 0.77
112 Familial defective apolipoprotein B-100: mild hypercholesterolaemia without atherosclerosis in a homozygous patient. Lancet 1992 0.77
113 Structural and compositional modifications of diabetic low-density lipoproteins influence their receptor-mediated uptake by hepatocytes. Eur J Clin Invest 1997 0.77
114 Relationship between plasma aldosterone concentration and soluble cellular adhesion molecules in patients referred to coronary angiography. Exp Clin Endocrinol Diabetes 2011 0.77
115 Apolipoprotein E (apoE) uptake and distribution in mammalian cell lines is dependent upon source of apoE and can be monitored in living cells. Neurosci Lett 2003 0.77
116 Apolipoprotein B(Arg3500----Gln) allele specific polymerase chain reaction: large-scale screening of pooled blood samples. J Lipid Res 1992 0.77
117 Evaluation of the Roche diagnostics LightCycler-Factor V Leiden Mutation Detection Kit and the LightCycler-Prothrombin Mutation Detection Kit. Clin Biochem 2000 0.77
118 Association of bone turnover markers with mortality in women referred to coronary angiography: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Osteoporos Int 2013 0.77
119 Diabetes and cardiovascular risk evaluation and management in primary care: progress and unresolved issues - rationale for a nationwide primary care project in Germany. Exp Clin Endocrinol Diabetes 2004 0.77
120 C-reactive protein predicts mortality in patients referred for coronary angiography and symptoms of heart failure with preserved ejection fraction. Eur J Heart Fail 2014 0.77
121 FH-Freiburg: a novel missense mutation (C317Y) in growth factor repeat A of the low density lipoprotein receptor gene in a German patient with homozygous familial hypercholesterolemia. Atherosclerosis 2000 0.76
122 Direct determination of lipoprotein(a) cholesterol by ultracentrifugation and agarose gel electrophoresis with enzymatic staining for cholesterol. Clin Chem 1995 0.76
123 Therapy with recombinant human erythropoietin reduces cardiac size and improves heart function in chronic hemodialysis patients. Am J Nephrol 1991 0.76
124 Homogeneous assay for direct determination of high-density lipoprotein cholesterol evaluated. Clin Chem 1996 0.76
125 Lifibrol enhances the low density lipoprotein apolipoprotein B-100 turnover in patients with hypercholesterolemia and mixed hyperlipidemia. Atherosclerosis 1999 0.76
126 [Effect of 2 low-dosage Gestodene or desogestrel containing ovulation inhibitors on sex hormones and lipid metabolism]. Geburtshilfe Frauenheilkd 1988 0.76
127 Analysis of plasma lipoproteins by ultracentrifugation in a new fixed angle rotor: evaluation of a phosphotungstic acid/MgCl2 precipitation and a quantitative lipoprotein electrophoresis assay. Clin Chim Acta 1986 0.76
128 Reference standardization and triglyceride interference of a new homogeneous HDL-cholesterol assay compared with a former chemical precipitation assay. Clin Chem 1998 0.76
129 Lipoproteins and apolipoproteins during the progression of chronic renal disease. Nephron 1988 0.75
130 Pseudo-pseudohypertriglyceridemia: a case of increased free glycerol without evidence for glycerol kinase deficiency. Clin Chem 1995 0.75
131 Time-dependent alterations in lipid metabolism during treatment with low-dose oral contraceptives. Am J Obstet Gynecol 1990 0.75
132 Uptake and metabolism of lipoproteins from patients with diabetes mellitus type II by glomerular epithelial cells. Nephrol Dial Transplant 1997 0.75
133 Cost effectiveness of coronary prevention. Eur Heart J 1999 0.75
134 Time-of-intake (morning versus evening) of extended-release fluvastatin in hyperlipemic patients is without influence on the pharmacodynamics (mevalonic acid excretion) and pharmacokinetics. Int J Clin Pharmacol Ther 2007 0.75
135 Lifibrol: first member of a new class of lipid-lowering drugs? Expert Opin Investig Drugs 1997 0.75
136 Simple precipitation-based method for the screening of type III hyperlipoproteinemia. Clin Chem 1999 0.75
137 Type I hyperlipoproteinemia due to a novel loss of function mutation of lipoprotein lipase, Cys(239)-->Trp, associated with recurrent severe pancreatitis. J Clin Endocrinol Metab 2000 0.75
138 Inhibition of HMG-CoA reductase with cerivastatin lowers dense low density lipoproteins in patients with elevated fasting glucose, impaired glucose tolerance and type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2004 0.75
139 Lipid and lipoprotein profiles in children with familial hypercholesterolaemia: effects of therapy. Eur J Pediatr 1998 0.75
140 Alterations in the coagulation system of active smokers from the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Adv Exp Med Biol 2015 0.75
141 Isolation of lipoprotein (a) using the regenerate of a dextran sulfate cellulose LDL apheresis system. Protein Expr Purif 1994 0.75
142 Long-term echocardiographic examinations in chronic hemodialysis patients substituted with recombinant human erythropoietin. Blood Purif 1990 0.75
143 Precipitation of LDL with sulfated polyanions: three methods compared. Clin Chim Acta 1988 0.75
144 The use of atorvastatin treatment in usual care environments: pooled analysis of six prospective, observational studies in 90,535 patients. Int J Clin Pharmacol Ther 2004 0.75
145 Vitamin D in early life: good or bad for food allergies? Allergy 2013 0.75
146 Adding albumin normalizes electrophoretic mobility of lipoproteins in sera with high concentrations of free fatty acids. Clin Chem 1996 0.75
147 [Recommendations for statin therapy in the elderly]. Internist (Berl) 2004 0.75
148 Apolipoprotein E and beta A4-amyloid: signals and effects. Biochem Soc Symp 2001 0.75
149 Effects of cigarette smoking on plasma lipids, apolipoproteins, and lipoprotein(a) in healthy subjects. Clin Chem 1994 0.75
150 Association between asymmetric dimethylarginine and neopterin in patients with and without angiographic coronary artery disease. Scand J Immunol 2009 0.75
151 A randomized crossover comparison of two low-dose contraceptives: effects on serum lipids and lipoproteins. Am J Obstet Gynecol 1985 0.75
152 The significance of genetic polymorphisms in modulating the response to lipid-lowering drugs. Pharmacogenomics 2001 0.75
153 [Evidence based medicine: theoretical bases and current misuse for cost cutting in the public health sector]. Internist (Berl) 2007 0.75
154 [Guidelines for lowering lipids are too infrequently observed. Results of a retrospective study of coronary heart disease patients]. MMW Fortschr Med 2000 0.75
155 Six methods for the determination of C-peptide evaluated. Clin Chem Lab Med 1999 0.75
156 Clinical pharmacology of the hypocholesterolemic agent K 12.148 (lifibrol) in healthy volunteers. Eur J Clin Pharmacol 1991 0.75
157 [Can antioxidants prevent atherosclerosis?]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2006 0.75
158 Biosensing of arteriosclerotic nanoplaque formation and interaction with an HMG-CoA reductase inhibitor. Acta Physiol Scand 2002 0.75
159 Separation of apolipoproteins of human very low density lipoproteins by chromatofocusing. J Clin Chem Clin Biochem 1983 0.75
160 [High-density lipoprotein (HDL) and cholesteryl ester transfer protein (CETP): role in lipid metabolism and clinical meaning]. MMW Fortschr Med 2010 0.75
161 Quantification of human serum lipoprotein Lp(a): zone immunoelectrophoresis assay, a new sensitive method as compared to electroimmuno assay. Clin Chim Acta 1983 0.75
162 Additional comments on pre-analytical aspects of lipoprotein measurement. Clin Lab 2000 0.75
163 Smoking denial in cardiovascular disease studies. Adv Exp Med Biol 2013 0.75
164 Decreased binding of apolipoprotein (a) to familial defective apolipoprotein B-100 (Arg3500-->Gln). A study of the assembly of recombinant apolipoprotein (a) with mutant low density lipoproteins. J Biol Chem 1994 0.75
165 [Statins for all seniors?]. MMW Fortschr Med 2002 0.75
166 Risk factors associated with the metabolic syndrome in abdominal obesity. Clin Obes 2012 0.75
167 A novel assay for cytosolic 3-hydroxy-3-methylglutaryl-coenzyme A synthase activity using reversed-phase ion-pair chromatography: demonstration that Lifibrol (K12.148) modulates the enzyme activity. J Lipid Res 1995 0.75
168 New immunoseparation-based homogeneous assay for HDL-cholesterol compared with three homogeneous and two heterogeneous methods for HDL-cholesterol. Clin Chem 1998 0.75
169 Midazolam and its metabolites in brain death diagnosis. Int J Clin Pharmacol Ther 2005 0.75
170 Insufficient accuracy and specificity of polyanion precipitation methods for quantifying low-density lipoproteins. Clin Chem 1990 0.75
171 Effect on lipid metabolism of a biphasic desogestrel-containing oral contraceptive: divergent changes in apolipoprotein B and E and transitory decrease in Lp(a) levels. Contraception 1993 0.75
172 [Clinical trials: prerequisite of evidence-based oncology: reality, perspectives and a new tool recruited--the Internet]. Onkologie 2001 0.75
173 Apolipoproteins C-II and C-III in serum quantified by zone immunoelectrophoresis. Clin Chem 1987 0.75
174 [New AHA and ACC guidelines on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk : Statement of the D•A•CH Society for Prevention of Cardiovascular Diseases, the Austrian Atherosclerosis Society and the Working Group on Lipids and Atherosclerosis (AGLA) of the Swiss Society for Cardiology]. Internist (Berl) 2014 0.75
175 Cholesterol efflux from normal and Tangier disease fibroblasts into normal, high-density lipoprotein-deficient, and apolipoprotein E-deficient plasmas. Metabolism 2000 0.75
176 Typing of the HLA-DRB3 gene by temperature gradient gel electrophoresis. Prediction of the resolution of four allelic fragments by computational simulation of DNA melting. J Immunol Methods 1994 0.75